To combat high failure rates in CNS, Autobahn designed its Phase 2 study with the statistical power of a Phase 3 trial (+90%). This capital-intensive approach aims to get a definitive answer on drug efficacy early, increasing confidence for a successful Phase 3 replication and avoiding larger, later-stage flameouts.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

An analysis of over 17,000 oncology drug development trajectories revealed that trials incorporating biomarkers had almost twice the overall success probability (10%) compared to those without (5%). This success boost is most significant in early-phase (Phase 1 and 2) trials.

Unlike typical safety-focused Phase 1 trials, Jade's trial for IgA nephropathy in healthy volunteers provides highly translatable efficacy data. Measuring the drop in IgA, a key biomarker, in healthy subjects directly predicts the drug's clinical activity in patients, significantly de-risking later-stage development before treating a single patient.

For early-stage biotech companies, saving money by limiting initial drug substance characterization is a false economy. A comprehensive, state-of-the-art characterization before Phase 1 is essential to de-risk the program by identifying molecular issues before they become catastrophic problems in late-stage development.

Actis de-risks its drug development by using a platform where physicians can verify target engagement with imaging in early trials. This strategy confirms the drug is reaching the tumor, providing a crucial go/no-go signal long before expensive late-stage trials.

Gilead has tightened its criteria for advancing projects, demanding a deep mechanistic understanding before committing significant resources. This involves validating the target, understanding its biological impact preclinically, and identifying biomarkers—moving beyond just a promising hypothesis to a de-risked scientific thesis.

Unusually for a Phase 1 safety trial, Gain Therapeutics measured lipid levels in patients' cerebrospinal fluid. They observed a decrease in the target toxic lipids, providing strong, early biological evidence that the drug reaches the brain and works as intended. This de-risks future development by establishing a clear biomarker of effect.

Instead of waiting years for survival data, Longeveron used MRI to measure 'tricuspid regurgitation' (blood leaking backward in the heart) at one year. A statistically significant reduction provided a strong, early signal that the therapy was improving heart function, justifying progression to a larger pivotal trial.